2,894
edits
Psilocybin: Difference between revisions
m
no edit summary
mNo edit summary |
|||
| Line 16: | Line 16: | ||
== Depression Dosage == | == Depression Dosage == | ||
[[File:Psilocybin depression treatment.png|thumb|'''Figure 3'''. Depression symptom reduction from placebo, low dose and therapeutic dose of psilocybin.]] | [[File:Psilocybin depression treatment.png|thumb|'''Figure 3'''. Depression symptom reduction from placebo, low dose and therapeutic dose of psilocybin.]] | ||
Best practice indicates that a body weight derived dosage of psilocybin of 0.3mg / kg or 25mg should be used<ref>'''Pharmacokinetics of escalating doses of oral psilocybin in healthy adults'''. Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Clin Pharmacokinet. (2017) 56:1543–54. </ref>. In the realm of magic mushrooms this is approximately 2.5 grams of dried ''Psilocybe cubensis''. | Best practice indicates that a body weight derived dosage of psilocybin of 0.3mg / kg or 25mg should be used<ref>'''Pharmacokinetics of escalating doses of oral psilocybin in healthy adults'''. Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Clin Pharmacokinet. (2017) 56:1543–54. </ref>. In the realm of [[magic mushrooms]] this is approximately 2.5 grams of dried ''Psilocybe cubensis''. This dose is given as follows: | ||
1. Recruitment and [[Psychedelic Therapy Inclusion and Exclusion Criteria|medical screening]]. Tapering of other medicines if needed. | |||
2. Prep sessions 1 and 2 spaced over 2 weeks. | |||
3. '''Day 0''': 1st Psilocybin 25mg dose. | |||
4. '''Day 1''': 90 minute integration session. | |||
5. '''Day 8''': 2nd Psilocybin 25mg dose. | |||
6. '''Day 9''': 90 minute integration session. | |||
These standard doses has been found to have substantially better clinical outcomes than lower doses such 10mg or microdosing<ref>'''Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'''. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via <nowiki>https://www.nejm.org/doi/full/10.1056/NEJMoa2206443</nowiki></ref> (see '''Figure 3'''). This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.<ref name=":0">'''Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels'''. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9</ref> | These standard doses has been found to have substantially better clinical outcomes than lower doses such 10mg or microdosing<ref>'''Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'''. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via <nowiki>https://www.nejm.org/doi/full/10.1056/NEJMoa2206443</nowiki></ref> (see '''Figure 3'''). This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.<ref name=":0">'''Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels'''. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9</ref> | ||